Commemorating 25 years of fighting pancreatic cancer
Learn More

Hirshberg Foundation for Pancreatic Cancer Research

Dedicated to advancing pancreatic cancer research and providing support to patients and their families.

Donate
  • ABOUT THE FOUNDATION
    • Agi’s Story
    • About Us →
      • Mission
      • Directors/Trustees
      • Scientific Advisory Board
      • How Our Journey Began
    • COVID-19 Resources
    • News →
      • Latest News
      • Research News
      • Foundation News
      • UCLA Activity Summary Reports
      • Newsletters
      • Press Room
    • Contact
  • PANCREATIC CANCER
    • About the Pancreas →
      • The Pancreas
      • Cancer Cells
      • Risk Factors
      • Symptoms
      • Diagnosis
      • Prognosis
      • Staging
      • Second Opinion
    • Treatment Options →
      • Surgery
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Alternative Treatment Options
      • Clinical Trials
    • Supportive Care →
      • Obstructions
      • Pain Control
      • Nutrition
      • Cannabis
      • Palliative Care
    • Pancreatic Cancer Facts
    • Glossary of Terms
    • Frequently Asked Questions
  • RESEARCH
    • Seed Grant Program →
      • Seed Grant Recipients
      • Frequently Asked Questions
    • UCLA Program →
      • UCLA Center for Pancreatic Diseases
      • Basic Research
      • Translational Research
      • Sahin-Toth Laboratory
      • UCLA Pancreas Tissue Bank
      • UC Pancreatic Cancer Consortium
      • Simms/Mann Psychosocial →
        • Insights into Cancer
    • American Pancreatic Association
    • NIH Funded Projects
  • PATIENTS & CAREGIVERS
    • Patient Support
    • Caregivers
    • Symposium →
      • Symposium Presentations
    • Patient & Family Webinars
    • Genetic Counseling
    • Financial Aid
    • Resources →
      • Symptom Management Workbook
      • Guidelines for Patients: Pancreatic Cancer
      • Creating Your Health Care Team
      • A Virtual Advocate
      • Patient Tools
  • HOW YOU CAN HELP
    • You Can Help Funds
    • Host Your Own Event
    • Event Calendar
    • Get Inspired
    • November Awareness Month →
      • World Pancreatic Cancer Day
    • Other Ways to Give →
      • Shop Online Store
      • Wedding Program
      • Volunteer
      • Planned Giving
      • Car Program
  • SEARCH
Home / Research / Seed Grant Program / Seed Grant Recipients / Shili Xu, PhD

Shili Xu, PhD

Shili Xu, PhD
Shili Xu, PhD
Associate Project Scientist
Surgery/Division of Surgical Oncology
University of California, Los Angeles (UCLA)

A Precision Combination Therapy for Pancreatic Tumors with Interferon Signaling

Overview

Pancreatic tumors demonstrate extensive changes in nutrient metabolism and profound inflammation compared to healthy pancreas tissue, with both supporting pancreatic tumor growth. However, how inflammatory factors affect nutrient metabolism in pancreatic tumor cells is not clear. Among the inflammatory factors, two major classes of interferons (IFN)s, type I and II IFNs, are particularly important in pancreatic cancer. Type I IFNs are found in chronic inflammation in many pancreatic tumors, and type II IFN is often found in pancreatic tumors treated with cancer immunotherapies. We aim to model chronic inflammation and immunotherapies in pancreatic tumors in laboratory experiments by culturing pancreatic cancer cells with type I and II IFNs, respectively. Nicotinamide adenine dinucleotidie (NAD) is an essential metabolite for cancer cell proliferation and survival. Our previous research showed that the presence of IFNs lowers NAD levels, changes how pancreatic cancer cells synthesize NAD, and also increases their sensitivity to drugs that even further decrease NAD levels. We hypothesize that these specific changes in NAD metabolism in pancreatic cancer, with chronic inflammation and/or with immunotherapies, provide potential therapeutic opportunities. In our proposed study, we will comprehensively test our hypothesis in cell culture and animal models of pancreatic cancer with chronic inflammation and with immunotherapies, using clinically safe agents to decrease NAD levels in pancreatic cancer cells. If successful, our findings will be applicable for clinical treatment of subsets of pancreatic cancers with chronic inflammation and/or with immunotherapies.

Research

  • Seed Grant Program
    • Seed Grant Recipients
      • Alexandra Demcsak M.D., Ph.D.
      • Evan R. Abt, Ph.D.
      • Jason Link, Ph.D.
      • Kamini Singh Ph.D.
      • Ethan V Abel, PhD
      • Michael Feigin, Ph.D.
      • Mirunalini Ravichandran, Ph.D.
      • Simon Schwörer, Ph.D.
      • Vanaja Konduri, Ph.D.
    • Frequently Asked Questions
  • UCLA Program
    • UCLA Center for Pancreatic Diseases
    • Basic Research
    • Translational Research
    • Sahin-Toth Laboratory
    • UCLA Pancreas Tissue Bank
    • UC Pancreatic Cancer Consortium
    • Psychosocial Care via Simms/Mann
      • Insights into Cancer
  • American Pancreatic Association (APA)
  • NIH Funded Projects

Patient Support Resources

from the comfort of your home


Our Webinar Library »

Never Give Up.
The journey continues with an end in sight.
Our Stories »
SUBSCRIBE
Our Free E-Newsletter
Sign up to receive information on breaking news, patient programs and upcoming events.
You can custom tailor your subscriptions and unsubscribe at any time.
  • How You Can Help
  • Make A Donation
  • Host an Event
  • Shop Online Store
  • Signature Events
  • L.A. Cancer Challenge
  • Tour De Pier
  • Hirshberg Training Team
  • More
  • News
  • Press
  • Contact

Stay Connected

Join Our E-newsletter

  • Legal and Privacy
  • Contact Us